Li Ziyuan: There are no matters that should be disclosed but not disclosed. Li Ziyuan issued a change announcement. After the company's self-inspection, the company's current production and operation activities are normal, there is no major adjustment in the market environment or industry policies, and the internal production and operation order is normal; , the company and the controlling shareholder and actual controller of the company have no matters that should be disclosed but not disclosed.Ministry of Finance of the Republic of Korea: We will pay close attention to the financial and foreign exchange market trends and take adequate measures to curb excessive fluctuations in the foreign exchange market.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.
Sichuan issued 30-year ordinary special local bonds, with a scale of 35.4 billion yuan, an issue interest rate of 2.2000%, a marginal multiple of 1.58 times and an expected multiple of 2.19.Yuanyuan Communication: The plan being evaluated and negotiated between the company and toy manufacturers does not involve ByteDance, and the results of subsequent negotiations are still uncertain.Policy combination boosts confidence, and public offering: China's assets will usher in a further increase in valuation. On December 9, the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting to analyze and study the economic work in 2025. A number of public offerings said that the meeting sent a very positive signal. At present, the economy is resilient, the investor structure is constantly optimized, and the market activity continues to increase. China assets may have an opportunity to raise their valuations again. From the perspective of funds, Jing Shun Great Wall Fund analyzed that the current A-share market is in the most active stage since 2015, and there are many potential bulls in the market. Policy expectations are expected to drive incremental funds into the market, forming a resonance between emotions and funds. (SSE)
Nikkei futures opened down 95 points at 39,290 on the Singapore Stock Exchange.General Motors (GM): The unmanned business Cruise and GM Technical team will be merged, and the plan is expected to be completed in the first half of 2025. According to the priority of GM's capital allocation, GM will no longer fund Cruise's self-driving taxi development business.Australia's S&P/ASX200 index opened down 12.60 points, or 0.15%, at 8380.4 points on Wednesday, December 11th.